Acute Kidney Injury, Cardiac Surgery
Conditions
Keywords
angiopoietin, endothelial injury, MACCE
Brief summary
Cardiac surgery and cardiopulmonary bypass can lead to systemic organ failure trough excess inflammation and endothelial injury. The angiopoietin family represented by angiopoietin 1 and 2 can reflect endothelial injury by a decrease in angiopoietin 1 and an increase in angiopoietin 2. The investigators hypothesized that angiopoietin dysregulation could reflect organ failure related to cardiac surgery. The purpose of this project is to assess the association between angiopoietin dysregulation and adverse outcomes on cardiac surgery.
Interventions
OTHERblood sample
5 ml blood sample will be withdrawn at the surgery start and at the surgery end
Sponsors
Centre Hospitalier Universitaire, Amiens
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* adult patient scheduled for cardiac surgery under cardiopulmonary bypass
Exclusion criteria
* patient less than 18 years old, * redo surgery, * urgent surgery, * endocarditis, * aortic root repair surgery * aortic dissection * heart beating surgery, * heart transplantation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Correlation between abnormal angiopoietin 1 concentration (ng/ml) and number of major cardiovascular event | 28 days | major cardiovascular event are myocardial infraction, stroke, acute kidney injury, cardiovascular death |
| correlation between occurence of abnormal angiopoietin 2 concentration (ng/ml) and occurence of major cardiovascular event | 28 days | major cardiovascular event are myocardial infraction, stroke, acute kidney injury, cardiovascular death |
Secondary
| Measure | Time frame |
|---|---|
| Correlation between abnormal angiopoietin 1 concentration (ng/ml) and mortality at 3 months | 3 months |
| Correlation between abnormal angiopoietin 2 concentration (ng/ml) and mortality at 3 months | 3 months |
| Correlation between abnormal angiopoietin 1 concentration (ng/ml) and mortality at 6 months | 6 months |
| Correlation between abnormal angiopoietin 1 concentration (ng/ml) and number of postoperative pulmonary complications | 28 days |
| Correlation between abnormal angiopoietin 1 concentration (ng/ml) and mortality rate at 12 months | 12 months |
| Correlation between abnormal angiopoietin 2 concentration (ng/ml) and mortality rate at 12 months | 12 months |
| Correlation between occurence of abnormal angiopoietin 2 concentration (ng/ml) and mortality at 6 months | 6 months |
| Correlation between abnormal angiopoietin 2 concentration (ng/ml) and number of postoperative pulmonary complications | 28 days |
Countries
France
Contacts
Primary ContactOsama ABOU ARAB, MD
Outcome results
None listed